The FDA’s BPC-157 Vote, Explained

One of peptide therapy’s biggest regulatory weeks of the year. Here’s what happened, what it changes today, and what it doesn’t.

The advisory committee voted on six peptides

On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed peptides for the 503A Bulks List, the substances licensed pharmacies may compound into patient-specific prescriptions. It recommended six by narrow margins:

• BPC-157: 8–6, 1 abstention
• KPV: 8–6, 1 abstention
• TB-500: 8–6, 1 abstention
• MOTS-c: 7–5, 2 abstentions
• Semax and Epitalon: similarly tight margins

A seventh candidate, emideltide, was rejected. Several outlets noted the votes ran against the FDA’s own scientific reviewers. [AJMC; The Maha Report]

What the vote changes, and what it doesn’t

It’s a recommendation, not a rule. Before legal compounding:

• The HHS Secretary must accept the recommendation.
• The FDA must complete notice-and-comment rulemaking.
• Only after a final rule may pharmacies compound these substances.

There’s no published timeline, and none of the six are FDA-approved drugs. [NPR, Jul 22, 2026]

FDA-approved peptide drugs keep advancing

Protagonist Therapeutics and Takeda’s MIMRYLO (rusfertide), a hepcidin-mimetic peptide, received full FDA approval for polycythemia vera. “Peptide” isn’t one regulatory category: some are approved drugs, some are under compounding review, and others are sold online with no oversight.

Why this matters if you’re considering peptide therapy

• Physician-guided only.
• Licensed U.S. pharmacies.
• Plans that adapt as rulemaking moves.

FAQ

This article is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the guidance of a licensed physician.

Sources

• AJMC — FDA Panel Backs 6 Peptides for Compounding
• NCPA — FDA advisory committee nominates six peptides
• NPR — FDA panel to consider easing restrictions on peptide production
• The Maha Report — FDA Panel Clears 6 of 7 Peptides